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Invasive fungal diseases have increased many fold over the past
50 years. Current treatment regimens typically require prolonged
administration of antifungal medications that can have significant
toxicity. Moreover, our present potent antifungal armamentar-
ium fails to eradicate fungal pathogens from certain compromised
hosts. Additionally, invasive fungal diseases continue to have
unacceptably high mortality rates. A growing body of work has
focused on the utility of vaccines and/or immunotherapy as a
powerful tool in combating mycoses, either for the active treat-
ment, as an adjuvant, or in the prevention of specific fungal
pathogens. This Research Topic “Vaccines and Immunotherapy
against fungi: a new frontier” in Frontiers in Fungi and their
Interactions details the exciting progress in developing vaccines
and immunotherapy for fungi.
The critical requirement for understanding the degrees of
engagement of host defense pathways in responding to fun-
gal invasion has led to an increased focus on host-pathogen
interactions. In this Research Topic, Carvalho et al. (2012)
review our current progress on this endeavor and underscore the
need for coordinated cross-disciplinary future efforts. A major
focus of the special Topic is the advance of vaccine strategies
against major fungal pathogens. To this extent, the issue focuses
on developments in vaccine strategies against Candida albicans
(Vecchiarelli et al., 2012), Aspergillus fumigatus (Diaz-Arevalo
et al., 2012), Cryptococcus neoformans (Hole and Wormley,
2012), and Paracoccidioides brasiliensis (Travassos and Taborda,
2012). Progress in optimizing adjuvants for a vaccine against
P. brasiliensis is also presented (Mayorga et al., 2012). Shifting
host responses to facilitate fungal clearance is shown in work
utilizing ArtinM, a D-mannose binding lectin from Artocarpus
heterophyllus, which modulates immunity against P. brasilien-
sis (Ruas et al., 2012). Along this line, information is presented
regarding the immunomodulatory effects of fungal immunogens
and how they impact disease (Rodrigues and Nimrichter, 2012).
The utility of antibody based therapeutic approaches is presented
against a specific fungus, Histoplasma capsulatum (Nosanchuk
et al., 2012), and as a broad-spectrum therapeutic using antibody
labeled with fungicidal nuclides (Nosanchuk and Dadachova,
2012). A therapeutic monoclonal antibody in early phase research
for sporotrichosis is also detailed (Almeida, 2012). Moreover, the
broad potential of antibody-derived “killer peptides” is presented
(Magliani et al., 2012). Finally, new information about the anti-
fungal activity of “old” drugs is discussed. Hydroxyurea is shown
to impact the sphingolipid pathway underscoring the role of these
compounds in fungal biology (Tripathi et al., 2012). The diverse
activities of Amphotericin B on both fungi, impacting ergosterol
stability and cellular morphology, and host cells, engaging pattern
receptors, is critically summarized (Mesa-Arango et al., 2012).
In sum, these articles broadly paint the current spectrum
of investigations on host-pathogen interactions and provide a
review of the state-of-the-art in vaccinology and immunother-
apy against fungi. The information presented also underscores the
rich areas for future study, all promising improved therapeutics
against fungal invaders.
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